Press "Enter" to skip to content

American Cancer Society Recommends Earlier Prostate Cancer Screening for Men

The American Cancer Society released updated prostate‑cancer screening guidelines on Nov. 12, shifting from a shared‑decision model to a clear recommendation for regular testing among men at average risk. Under the new protocol, men aged 50 to 69 should have a prostate‑specific antigen (PSA) blood test every two years.

Key Recommendations

For Black men, the Society advises beginning annual PSA screening at age 45, regardless of family history. Men who have a father, brother or son diagnosed with prostate cancer are also urged to start at 45, with the testing interval determined by the specifics of their family history. Men aged 70 to 74 should discuss the benefits and drawbacks of continued screening with their physicians, while routine testing is not recommended for those 75 and older.

A PSA level of 3 ng/mL or higher in men under 70 triggers a repeat test to confirm the result. Elevated PSA can stem from non‑cancer causes such as an enlarged prostate, inflammation or infection. The Society emphasizes that screening may uncover slow‑growing cancers that never become harmful, and recommends that patients and providers weigh the benefits against possible harms, considering active surveillance for low‑risk disease.

Rationale and Expected Impact

Prostate cancer remains the second‑leading cause of cancer death among U.S. men. When the disease is confined to the prostate or nearby tissues, the five‑year relative survival rate approaches 100%, according to the Society. Dr. Ash Tewari, chair of urology at Icahn School of Medicine at Mount Sinai, noted that “men think it is going to happen to someone else,” and stressed that treatment success rates are exceedingly high. He added, “We know how to cure 95% of them,” highlighting advances in surgery and medication that improve outcomes when cancer is caught early.

The Society projects that more than 333,000 men will be diagnosed with prostate cancer in 2026, and about 36,000 will die from the disease. By encouraging earlier and more consistent screening, the guidelines aim to reduce mortality and increase the proportion of cancers caught at a stage where survival is nearly guaranteed.

Outreach Efforts

To broaden access, Dr. Tewari and Mount Sinai have deployed mobile prostate‑cancer screening units. The first vehicle, the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit, began operating in New York City in 2022. A second bus was sent to the Atlanta Falcons‑Chicago Bears game at Mercedes‑Benz Stadium, where the Winship Cancer Institute at Emory University provided free screenings in partnership with the Falcons.

Public awareness campaigns accompany the mobile units. Actress Brooke Shields recently appeared in a public service announcement with Dr. Tewari, sharing her personal connection—her father died of prostate cancer at 61—and urging men to discuss screening early. The initiative, dubbed “Million Strong Men,” targets screening more than one million men nationwide.

“Prostate cancer is treatable when detected early,” Dr. Tewari said, adding that families often avoid the conversation until a diagnosis forces it. By normalizing dialogue and making testing convenient, the Society hopes to shift the cultural perception of prostate health and lower the disease’s death toll.